Clay Siegall, CEO of Immunome, Inc., purchased 7,278 shares of the company’s stock on December 19, 2023, in a transaction valued at approximately $149,053.44. The shares were acquired at an average price of $20.48 each. Following this purchase, Siegall’s total holdings in Immunome increased to 860,525 shares, valued at about $17.6 million, representing a 0.85% rise in his ownership.
This transaction was disclosed in a filing with the Securities and Exchange Commission (SEC), which is publicly accessible via the SEC website. The acquisition comes as shares of Immunome opened at $21.44 on the following Monday, reflecting a strong interest in the company within the market.
Market Performance and Financial Overview
As of the latest data, Immunome’s market capitalization stands at $1.97 billion with a price-to-earnings (PE) ratio of -7.27. The company’s stock has seen fluctuations, with a 12-month low of $5.15 and a high of $25.30. The current 50-day moving average price is $17.68, while the 200-day moving average price is $12.73.
In its most recent earnings report, released on November 6, 2023, Immunome reported an earnings per share (EPS) of -$0.65, missing analysts’ expectations of -$0.57 by $0.08. The company has also recorded a negative return on equity of 76.50% and an exceptionally high negative net margin of 1,687.08%. Analysts forecast an EPS of -$2.21 for the current fiscal year.
Institutional Investment Activity
Recent trading activity indicates significant movements among institutional investors regarding Immunome shares. Vanguard Group Inc. increased its holdings by 43.4% in the first quarter, acquiring an additional 1,303,753 shares, bringing its total to 4,307,191 shares valued at approximately $28.99 million.
Furthermore, the Principal Financial Group Inc. ramped up its holdings by 222.3% in the third quarter, now owning 1,104,938 shares worth $12.94 million. Another notable investor, Woodline Partners LP, raised its position by 69.0%, acquiring 676,804 shares during the same period, now holding 1,657,729 shares valued at approximately $11.16 million.
These movements illustrate a considerable interest in Immunome, with institutional investors now owning 44.58% of the company’s stock.
Immunome, Inc. is recognized as a clinical-stage biotechnology firm focused on innovative antibody-based therapeutics for oncology and infectious diseases. Utilizing a proprietary platform, the company aims to discover fully human monoclonal antibodies that engage the immune system in novel ways. Its lead oncology program, IMM-BCP-01, is currently undergoing early-stage clinical trials targeting breast cancer antigens.
For further updates and insights, stakeholders can sign up for daily summaries of news and ratings related to Immunome and similar companies.
